Phase II of the study (June 2013 to May 2019) is sponsored by NHLBI and other institutes of NIH. Participants, who were examined at baseline, will undergo a second examination and will continue to be followed annually to assess changes in health and health outcomes of interest. The second examination, which starts in October 2014, will include assessment of cardiovascular risk factors, echocardiography, and blood and urine tests. Information on gestational diabetes will be collected. Genetic information will be analyzed to determine if health and disease findings can be linked to specific gene variants.